T cell responses induced by allergen-specific immunotherapy

Clinical and Experimental Immunology

Volumn 161, Issue 1, 2010, Pages 10-18

  Maggi, E ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allergen specific immunotherapy; Allergy; Cytokines; Regulatory T cells; T effector cells

Indexed keywords

ALLERGEN; BEE VENOM; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYMENOPTERA VENOM; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MESSENGER RNA; POLLEN ANTIGEN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALLERGIC ASTHMA; ALLERGIC REACTION; ANTIGEN SPECIFICITY; APOPTOSIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOLECULAR MECHANICS; NATURAL KILLER T CELL; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77953246494     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04148.x     Document Type: Review

References (99)

1. Creticos PS. Immunotherapy with allergens. JAMA 1992 268 : 2834 2839.
2. Malling H-J, Weeke B. EAACI position paper: immunotherapy. Allergy 1993 48 : 9 35.
3. Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 81 : 401 405.
4. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999 341 : 468 475.
5. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006 61 : 198 201.
6. Durham SR, Varney VA, Gaga M et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999 29 : 1490 1496.
7. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993 92 : 644 651.
8. Nish WA, Charlesworth EN, Davis TL et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994 93 : 484 493.
9. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999 103 : 468 475.
10. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004 113 : 1025 1034.
11. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 2005 60 : 4 12.
12. Radulovic C, Calderon M, Wilson S, Durham SR. Sublingual immunotherapy for allergic rhinitis: An updated Cochrane systematic review and meta-analysis. Allergy 2007 62 (s83 167 171.
13. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized clinical trials using the Cochrane Collaboration Method. Allergy 2006 61 : 1162 1172.
14. Penagos M, Passalacqua G, Campalati E et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3-18 years of age. Chest 2008 133 : 599 609.
15. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009 60 : 279 291.
16. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003 111 : 437 448.
17. Bousquet J, Van Cauwenberge P, eds. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 : S240 5.
18. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. J Allergy Clin Immunol 2009 124 : 157 161.
19. Röder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: A systematic review. Pediatr Allergy Immunol 2008 19 : 197 207.
20. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA(2)LEN meta-analysis. Allergy 2009 64 : 1570 1579.
21. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000 105 : 399 408.
22. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003 111 : 450 464.
23. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008 8 : 169 182.
24. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008 8 : 193 204. (Pubitemid 351323293)
25. Lee CG, Link H, Baluk P et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004 10 : 1095 1103.
26. Trompette A, Divanovic S, Visintin A et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009 457 : 585 588.
27. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008 181 : 7480 7488.
28. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007 204 : 1849 1861.
29. Cosmi L, De Palma R, Santarlasci V et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008 205 : 1903 1916.
30. Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, Gounni AS. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J Immunol 2006 177 : 4046 4071.
31. Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008 57 : 121 134.
32. Cosmi L, Maggi L, Santarlasci V et al. Demonstration of a small subset of human circulating memory CD161+ CD4+ T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 2010 125 : 222 230.
33. Louten J, Boniface K, Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009 123 : 1004 1011.
34. Rolland J, O'Hehir R. Immunotherapy of allergy: Anergy, deletion, and immune deviation. Curr Opin Immunol 1998 10 : 640 645.
35. Gardner LM, O'Hehir RE, Rolland JM. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFNgamma+ T cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol 2004 133 : 1 13.
36. Antúnez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol 2008 19 : 210 218.
37. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998 102 : 98 106.
38. Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R. TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol 2001 107 : 647 653.
39. Rolland J, Gardner LM, O'Heir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009 121 : 273 284.
40. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen stimulated T cell cultures. J Immunol 1995 154 : 4187 4194.
41. Till S, Walker S, Dickason R et al. IL-5 production by allergen stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997 110 : 114 121.
42. Ciprandi G, Sormani MP, Filaci G, Fenoglio D. Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy. Int Immunopharmacol 2008 8 : 1622 1625.
43. Kozutsumi D, Tsunematsu M, Yamaji T, Murakami R, Yokoyama M, Kino K. Cry-consensus peptide, a novel peptide for immunotherapy of Japanese cedar pollinosis, induces Th1-predominant response in Cry j 1-sensitized B10.S mice. Biol Pharm Bull 2006 29 : 2506 2509.
44. Sel S, Wegmann M, Sel S et al. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 2007 178 : 7805 7813.
45. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD41 T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon gamma. J Allergy Clin Immunol 1996 97 : 1356 1365.
46. Wilson DR, Nouri-Aria KT, Walker SM et al. Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001 107 : 971 976.
47. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 2002 105 : 56 62.
48. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit1mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005 116 : 73 9.
49. Plewako H, Wosinska K, Arvidsson M et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006 141 : 346 353.
50. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA1 cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997 99 : 254 260.
51. Plewako H, Wosinska K, Arvidsson M, Bjorkander J, Hakansson L, Rak S. Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy. Ann Allergy Asthma Immunol 2006 97 : 464 468.
52. Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005 60 : 1269 1274.
53. Lloyd CM, Hawrylowicz CM. Regulatory T cells in asthma. Immunity 2009 31 : 438 449.
54. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003 4 : 330 336.
55. Larchè M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006 18 : 745 750.
56. Grindebacke H, Wing K, Andersson AC, Suri-Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004 34 : 1364 1372.
57. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008 205 : 2887 2898.
58. Maggi L, Santarlasci V, Liotta F et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 2007 120 : 429 436.
59. Akdis CA. T cells in health and disease. J Allergy Clin Immunol 2009 123 : 1022 1023.
60. Pfefferle PI, Sel S, Ege MJ et al. PASTURE Study Group. Cord blood allergen-specific IgE is associated with reduced IFN-γ production by cord blood cells: The Protection against Allergy - Study in Rural Environments (PASTURE) study. J Allergy Clin Immunol 2008 122 : 711 716.
61. Van Overtvelt L, Wambre E, Maillere B et al. Assessment of Bet v 1-specific CD4-T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008 180 : 4514 4522.
62. Romagnani S. Coming back to a missing immune deviation as the main explanatory mechanism for the hygiene hypothesis. J Allergy Clin Immunol 2007 119 : 1511 1513.
63. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003 111 : 1255 1261.
64. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993 150 : 353 360.
65. McKinstry KK, Strutt TM, Buck A et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009 182 : 7353 7363.
66. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001 31 : 3704 3713.
67. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2009 121 : 1467 1472.
68. Ying S, Humbert M, Meng Q et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 2001 107 : 686 692.
69. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 2008 1074 1088.
70. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006 61 : 151 165. (Pubitemid 43381824)
71. Allam JP, Stojanovski G, Friedrichs N et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008 63 : 720 727.
72. Dehlink E, Eiwegger T, Gerstmayr M et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006 36 : 32 9.
73. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006 61 : 1184 1190.
74. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007 120 : 707 713.
75. O'Hehir RE, Gardner LM, de Leon MP et al. House dust mite sublingual immunotherapy: The role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009 180 : 936 947.
76. Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2010 21 : 174 184.
77. Incorvaia C, Frati F, Puccinelli P et al. Effects of sublingual immunotherapy on allergic inflammation. Inflamm Allergy Drug Targets 2008 7 : 167 172.
78. Gardner LM, Spyroglou L, O'Hehir RE, Rolland JM. Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 2004 59 : 1308 1317.
79. MacDonald AJ, Duffy M, Brady MT et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 2002 185 : 720 727.
80. Reefer AJ, Carneiro RM, Custis NJ et al. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J Immunol 2004 172 : 2763 2772.
81. Parronchi P, Sampognaro S, Annunziato F et al. Influence of both TCR repertoire and severity of the atopic status on the cytokine secretion profile of Parietaria officinalis-specific T cells. Eur J Immunol 1998 28 : 37 46.
82. Qian C, An H, Yu Y, Liu S, Cao X. TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 2007 109 : 3308 3315.
83. Bozza S, Zelante T, Moretti S et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 2008 180 : 4022 4031.
84. Mamessier E, Birnbaum J, Dupuy P et al. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006 36 : 704 713.
85. Jones SM, Pons L, Roberts JL et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009 124 : 292 300.
86. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin 10-production. Clin Exp Allergy 2006 36 : 261 272.
87. Stock P, Akbari O, Berry G, Freeman GJ, Dekruyff RH, Umetsu DT. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol 2004 5 : 1149 1156.
88. Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J Exp Med 2001 194 : F53 7.
89. Verhoef A, Alexander C, Kay AB, Larchè M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005 2 : 253 261.
90. Jankovic D, Kullberg MC, Feng CG et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007 204 : 273 283.
91. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007 204 : 285 297.
92. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007 204 : 239 243.
93. Häringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med 2009 206 : 1009 1017.
94. Gabrysová L, Nicolson KS, Streeter HB et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009 206 : 1755 1767.
95. Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M, Scheffold A. Notch regulates IL-10 production by T helper 1 cells. Proc Natl Acad Sci USA 2008 105 : 3497 3502.
96. Stumhofer JS, Silver JS, Laurence A et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007 8 : 1363 1371.
97. Vultaggio A, Nencini F, Fitch PM et al. Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 2009 182 : 880 899.
98. Lombardi V, Van Overtvelt L, Horiot S et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008 38 : 1819 1829.
99. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-Toll like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006 355 : 1445 1455.